78-44-4

White powder.

CARISOPRODOL(78-44-4) is a carbamate ester. Carbamates are chemically similar to, but more reactive than amides. Like amides they form polymers such as polyurethane resins. Carbamates are incompatible with strong acids and bases, and especially incompatible with strong reducing agents such as hydrides. Flammable gaseous hydrogen is produced by the combination of active metals or nitrides with carbamates. Strongly oxidizing acids, peroxides, and hydroperoxides are incompatible with carbamates.

Insoluble in water.

SYMPTOMS: The most common symptoms of exposure to this chemical are drowsiness and hives. Other symptoms may include nausea, vomiting, epigastric distress, vertigo, ataxia, tremors, agitation, irritability, headache, insomnia, fainting, hiccups, visual disturbances, asthma, fever, hypotension, excitement and paralysis.

Flash point data for this chemical are not available, but CARISOPRODOL it probably combustible.

Carisoprodol (CRM) (Item No. ISO60206) is a certified reference material categorized as a skeletal muscle relaxant. It also has sedative properties. Carisoprodol is regulated as a Schedule IV compound in the United States. Carisoprodol (CRM) (Item No. ISO60206) is provided as a DEA exempt preparation. This product is intended for research and forensic applications.

Carisoprodol (Item No. 30778) is an analytical reference standard categorized as a skeletal muscle relaxant. It also has sedative properties. Carisoprodol is regulated as a Schedule IV compound in the United States. This product is intended for research and forensic applications.

White Solid

Soma,Wallace,US,1959

Carisoprodol suppresses interneuronal action of reticular formation of the spinal cord. It is used as an adjuvant drug for loss of flexibility of skeletal muscle as well as for relieving pain caused therein. Synonyms of this drug are rela, soma, carisoma, and sanoma.

For the relief of discomfort associated with acute, painful, musculoskeletal conditions.

Muscle relaxant (skeletal)
Carisoprodol has an onset of action of ca. 30min and a duration of 4–6h. It is administered orally. Presumably, it acts by inhibiting interneuronal activity in the spinal cord and the brainstem reticular formation. Clinically effective doses are accompanied by drowsiness or dizziness; its mechanism may involve sedation.Its CNS depressant effects are additive with those of ethanol and other psychotropic agents. Carisoprodol has a low potential for drug dependence.

ChEBI: A carbamate ester that is the mono-N-isopropyl derivative of meprobamate (which is a significant metabolite). Carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alter tion in pain perception. It is used as a muscle relaxant in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm.

Carisoprodol is Prepared by reaction of 2-methyl-2-propyl-1,3-pro-panediol with phosgene and ammonium hydroxide, then with isopropyl isocyanate.

A cooled 10% solution of 1 mol of phosgene in toluene was added with stirring to a cooled solution of 1 mol of 2-methyl-2-propyl-1,3-propanediol and 2 mols of dimethylaniline also dissolved in toluene, at such a rate that the temperature of the mixture was maintained at about 25°C. The mixture was allowed to remain at this temperature for several hours, then cooled and extracted with cold 5% hydrochloric acid solution to remove the dimethylaniline. The toluene layer was dried using a suitable drying agent and the 2-methyl-2-propyl-3-hydroxypropyl chlorocarbonate used in subsequent reactions in the form of its solution in anhydrous toluene.
A quantity of solution obtained as described containing 0.1 mol of the chlorocarbonate was treated with 0.2 mol of anhydrous isopropylamine and allowed to react at ordinary room temperature. The solution was cooled, extracted with dilute hydrochloric acid and the organic layer concentrated by evaporation of the solvent. The crude monocarbamate was purified by distilling at 86° to 88°C at about 0.01 mm. It was a clear, viscous liquid.
21.7 g (0.1 mol) of N-isopropyl-2-methyl-2-propyl-3-hydroxypropylcarbamate and 7.5 g (0.11 mol) of anhydrous sodium cyanate are stirred in 200 ml anhydrous chloroform in a suitable vessel equipped with a gas inlet tube,stirrer and thermometer. While cooling the vessel, anhydrous hydrogen chloride is passed into the stirred mixture slowly for 5 hours maintaining the temperature between 0° and 5°C. Alternatively ethyl urethane in the presence of aluminum isopropylate as a catalyst may be used in place of the sodium cyanates and HCl. The mixture is then allowed to stand at room temperature overnight.
The solid material is separated by filtration and the chloroform solution concentrated to an oil under reduced pressure. The oil is dissolved in 50 ml of trichloroethylene, the solution treated with charcoal, filtered and the filtrate added to 125 ml of hexane. The crystalline material which forms on standing at refrigerator temperature is removed by filtration, washed with light petroleum ether and dried at about 50°C. Approximately 20 g of product are obtained. On recrystallizing from trichloroethylene-hexane, 17.8 g of purified compound are obtained, MP 89° to 91°C.

Rela (Schering); Soma (Medpointe).

Muscle relaxant

Carisoprodol, N-iso-propyl-2-methyl-2-propyl-1,3-propanediol (15.3.12), is synthesized by reacting 2-methyl-2-propylpropanediol-1,3 dicarbamate with 1 mol of phosgene, forming the chloroformate (15.3.10), from which carbamate (15.3.11) is formed by reacting it with isopropylamine. Reacting this with either urethane or sodium cyanate gives carisoprodol (15.3.12).